S F Hsu-Schmitz
Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients
Langer I, Oertli D, Harder F, Wight E, Moch H, Viehl C, Ladewig A, Hsu-Schmitz S, Gueller U, Zuber M. Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients. Eur J Surg Oncol 2008; 35:805-13.
28.11.2008Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients
28.11.2008Eur J Surg Oncol 2008; 35:805-13
Langer I, Oertli D, Harder F, Wight E, Moch H, Viehl C T, Ladewig A, Hsu-Schmitz S F, Gueller Ulrich, Zuber M
Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)
Thürlimann B, Castiglione M, Hsu-Schmitz S, Cavalli F, Bonnefoi H, Fey M, Morant R, Löhnert T, Goldhirsch A. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK). European journal of cancer (Oxford, England : 1990) 1997; 33:1017-24.
01.06.1997Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)
01.06.1997European journal of cancer (Oxford, England : 1990) 1997; 33:1017-24
Thürlimann Beat, Castiglione M, Hsu-Schmitz S F, Cavalli F, Bonnefoi H, Fey M F, Morant R, Löhnert T, Goldhirsch A